Mankind Pharma: Decent outlook along with M&A catalyst
Mis à jour
The stock dropped 4% after BSV acquisition announcement on Friday slid a little more to support levels of 2045 and bounced back to close at 2063.
The Co. will be announcing earnings which if goes well, the company can break through 2,200 resistance and move upwards.
The company also has regulatory approvals pending from:
-Competition Commission of India
-Turkish Competition Authority
-Federal Ministry of Economic Affairs and Climate Action, Germany
If everything goes as planned these approvals could act as a further catalyst to the stock.
Analyst price the stock at:
Kotak: 2370Rs
Antique: 2438Rs
MOFSL: 2650Rs
Dolat: 2554Rs
avg upside of 21% from current price of 2063Rs
The Co. will be announcing earnings which if goes well, the company can break through 2,200 resistance and move upwards.
The company also has regulatory approvals pending from:
-Competition Commission of India
-Turkish Competition Authority
-Federal Ministry of Economic Affairs and Climate Action, Germany
If everything goes as planned these approvals could act as a further catalyst to the stock.
Analyst price the stock at:
Kotak: 2370Rs
Antique: 2438Rs
MOFSL: 2650Rs
Dolat: 2554Rs
avg upside of 21% from current price of 2063Rs
Note
Would add more at this price (2000 INR)
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.